Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nina Ditsch

Showing results (151-160 of 207) with videos related to

Pageof 21
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Geburtshilfe Und Frauenheilkunde|June 13, 2025
COGNITION-GUIDE - Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II StudyConstantin Pixberg, Christian Maurer, Katharina Smetanay, et al.
Breast (Edinburgh, Scotland)|March 27, 2025
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence riskVolkmar Müller, Manuel Hörner, Marc Thill, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2026
Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancerNatalie Herold, Christoph Engel, Dorothee Speiser, et al.
Lancet (London, England)|February 18, 2014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Lijun Zhang, Michael Untch, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022Maggie Banys-Paluchowski, Marc Thill, Thorsten Kühn, et al.
Breast Care (Basel, Switzerland)|September 26, 2022
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022Marc Thill, Diana Lüftner, Cornelia Kolberg-Liedtke, et al.
Breast Care (Basel, Switzerland)|September 28, 2019
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019Marc Thill, Christian Jackisch, Wolfgang Janni, et al.
Pageof 21

Showing results (151-160 of 207) with videos related to

Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Geburtshilfe Und Frauenheilkunde|June 13, 2025
COGNITION-GUIDE - Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II StudyConstantin Pixberg, Christian Maurer, Katharina Smetanay, et al.
Breast (Edinburgh, Scotland)|March 27, 2025
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence riskVolkmar Müller, Manuel Hörner, Marc Thill, et al.
European Journal of Cancer (Oxford, England : 1990)|June 24, 2026
Spectrum of double heterozygosity in individuals diagnosed with hereditary breast and ovarian cancerNatalie Herold, Christoph Engel, Dorothee Speiser, et al.
Lancet (London, England)|February 18, 2014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Lijun Zhang, Michael Untch, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
Journal of Medical Genetics|March 2, 2016
Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancerKarin Kast, Kerstin Rhiem, Barbara Wappenschmidt, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022Maggie Banys-Paluchowski, Marc Thill, Thorsten Kühn, et al.
Breast Care (Basel, Switzerland)|September 26, 2022
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022Marc Thill, Diana Lüftner, Cornelia Kolberg-Liedtke, et al.
Breast Care (Basel, Switzerland)|September 28, 2019
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019Marc Thill, Christian Jackisch, Wolfgang Janni, et al.
Pageof 21